Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Venous Thrombosis × apixaban × Clear all

Phase

Status

Sponsor Class

OTHER 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 4 Neoplasms 3 Pulmonary Embolism 2 Venous Thrombosis 1 Thrombosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma 1 Embolism 1

Interventions

Dalteparin 3 abelacimab 2 MAA868 2 edoxaban 1 calcium heparin 1 bemiparin 1 apixaban 1 Tinzaparin 1 Rivaroxaban 1 Nadroparin 1 Heparin, Low-Molecular-Weight 1 Heparin 1 Fondaparinux 1 Enoxaparin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05171049 2026-02-23

ASTER

Anthos Therapeutics, Inc.

Phase 3 Terminated

Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡